Comprehensive Review Reveals Cannabis Use Disorder Affects 10% of World’s 193 Million Cannabis Users

Nature Reviews primer synthesizes global evidence on epidemiology, treatment options, and policy implications

Key Takeaways

• Cannabis use disorder affects approximately 10% of the world’s 193 million cannabis users, representing 22.1 million people globally
• Risk increases substantially with frequency of use, affecting up to one-third of daily users and those who initiate use before age 16
• Effective psychosocial treatments exist including CBT, motivational enhancement therapy, and contingency management, but no pharmacological treatments are approved
• High rates of psychiatric comorbidity occur, with 70% of CUD patients having another mental health disorder
• Cannabis legalization may increase CUD prevalence through increased access to more potent, cheaper cannabis products

What This Document Is

This is a Nature Reviews Disease Primer – a type of authoritative narrative review that synthesizes current knowledge on a medical condition for both specialists and non-specialists. The authors, who are leading researchers in addiction medicine and public health, comprehensively review existing literature on cannabis use disorder without conducting new research or systematic meta-analysis. As a narrative review, it cannot establish new causal relationships or provide systematic quality assessment of included studies.

Study at a Glance

• Global cannabis users: 192 million (3.9% of adult population)
• CUD prevalence: 22.1 million cases (289.7 per 100,000)
• Risk among regular users: ~10%, up to 30% in daily users
• Psychiatric comorbidity: 70% have another mental disorder
• Treatment availability: Psychosocial only, no approved medications

The review covers a condition affecting millions globally, with substantial individual and public health impact. Cannabis use disorder represents an underappreciated consequence of the world’s third most commonly used controlled substance after alcohol and tobacco. Global CUD data remain incomplete, with estimates based on available national surveys.

What the Paper Found or Argued

The review presents convergent evidence that cannabis use disorder affects approximately 10% of cannabis users globally, with risk increasing to 30-40% among daily users. Psychosocial treatments including cognitive behavioral therapy, motivational enhancement, and contingency management can substantially reduce cannabis use but rarely achieve enduring abstinence. No pharmacological treatments have been approved for CUD, though cannabinoid agonists show promise.

The authors synthesize epidemiological data showing clear risk factors including frequency of use, early onset, and co-use with tobacco. CUD has high psychiatric comorbidity rates, with 70% having another mental health disorder. Cannabis legalization may increase CUD prevalence through increased access to potent, cheaper products, though the evidence base on legalization effects remains preliminary with limited long-term follow-up data.

How Strong Is the Evidence?

The authors employ a comprehensive narrative approach typical of Disease Primers, drawing on epidemiological surveys, clinical trials, meta-analyses, and policy research. They appropriately distinguish between established findings and emerging evidence, particularly regarding legalization effects.

Major strengths include comprehensive coverage of epidemiology, biology, treatment, and policy aspects; integration of global data sources and multiple research methodologies; clear acknowledgment of limitations and data gaps; and expert authorship with relevant clinical and research backgrounds. However, the review lacks systematic search methodology and quality assessment of included studies, provides limited critical appraisal of individual studies cited, relies on incomplete global data with bias toward high-income countries, and addresses legalization effects at an early stage of evidence development.

Where Interpretation Gets Difficult

Key interpretive challenges center on heterogeneity in CUD definitions across different diagnostic systems and countries, making global comparisons complex. The evidence on cannabis potency and CUD risk remains primarily associational with limited causal data. Self-selection bias affects treatment studies as those seeking treatment may differ systematically from the broader CUD population. Long-term outcomes data remain sparse for both treated and untreated populations.

Could Different Choices Have Changed the Conclusion?

More restrictive CUD definitions could substantially lower prevalence estimates. Focusing only on severe cases requiring clinical treatment would reduce estimated burden. Including only randomized controlled trial evidence would strengthen causal claims but severely limit scope. Excluding jurisdictions without robust surveillance systems would improve data quality but reduce global representativeness.

Why This Matters

This Nature Reviews Disease Primer provides the first comprehensive synthesis of global evidence on cannabis use disorder at a time when many jurisdictions are legalizing cannabis use, making understanding of CUD epidemiology and treatment critically important for public health policy. The review directly informs treatment guidelines in both medical and mental health settings while providing evidence base for policy decisions on cannabis legalization and regulation.

How This Fits With the Bigger Literature

The review’s greatest strength lies in its integration of diverse evidence sources – from global epidemiological surveys to clinical trials to emerging policy research. The authors successfully synthesize biological mechanisms, clinical presentations, treatment evidence, and public health implications into a coherent framework that serves both clinical and policy audiences. This integration may not capture all methodological nuances of individual studies, but provides valuable synthesis across typically siloed research areas.

Common Misreadings

The review should not be interpreted as equating cannabis use with cannabis use disorder – approximately 90% of users do not develop CUD. Readers should avoid assuming that all forms of cannabis carry equal risk – evidence suggests higher potency products may increase CUD risk. While CUD has effective psychosocial treatments, these should not be overstated as rarely achieving lasting abstinence. Correlation between legalization and CUD prevalence should not be automatically interpreted as causation given complex socioeconomic factors.

Bottom Line

Cannabis use disorder is a real condition that affects about 1 in 10 cannabis users worldwide, with higher risk for heavy users and those who start young. While effective psychological treatments are available, no medications are approved yet. The comprehensive evidence base synthesized in this review provides essential guidance for both clinical practice and evolving cannabis policy decisions.

References

Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021). Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 7(1), 1-24.